Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations

Introduction/Background

Pathophysiology and Progression of SLE

Common Lupus Symptoms

Global Prevalence of SLE

Comorbidities Associated With SLE

Sensitivity, Specificity of Selected Criteria for SLE: SLICC Classification

Unmet Needs in the Management of SLE

SLE: Therapeutic Goals and the Treat-To-Target Approach

Why Has It Been So Hard to Develop New Therapies for SLE?

BSR Guidelines for the Management of SLE: Treatment Strategies

Guidelines Standard of Care and the Use of Targeted Therapies for SLE

Efficacy and Safety Results for Belimumab in SLE: BLISS-52

Efficacy and Safety Results for Belimumab in SLE: BLISS-76

SLE Concomitant Treatment With Belimumab and Rituximab: Phase 2A Trial Results

New and Emerging Therapies for SLE

Anifrolumab for the Treatment of SLE: Results From a Phase 2b Trial

Ustekinumab for the Treatment of SLE: Results From a Phase 2 Trial

Baricitinib for the Treatment of SLE: Results From a Phase 2 Trial

Summary and Conclusions

Abbreviations

Abbreviations (cont)